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1. ABSTRACT: 
Tumors mainly originate from epithelial and mesenchymal cells, majority of which are from 
epithelial origin. There are certain mechanism like EMT and MET which plays a critical role 
in malignant tumors or cancer progression. There are various other phenomenon and 
mechanisms occurring at the molecular and cellular level which are yet to be discovered. 
Success in unraveling such a mystery can give clue to understand the fatal disease like 
cancer. Roles of genes involved in various cancers and their expression in different forms of 
cancer as well as in normal condition can give an insight about cancer. This study could be 
carried out using microarray analysis. Present work mainly focuses to understand the 
similarity and dissimilarity between the tumors of epithelial and mesenchymal origin by 
microarray analysis of differentially expressed genes through Genespring software. Gene 
ontology analysis was also carried out through Genomatix software and two genes (ABCA8 
and SMC4) were selected for experimental validation based upon their regulation and 
association with cancer. Expressions of these two genes were experimentally validated 
through qRT-PCR with respect to housekeeping gene beta-actin in the HeLA cell line, a 
cervical cancer cell line. Studies like this can help us to understand the behavior of different 
types of cancer at the molecular and cellular level, thereby developing an effective treatment 
measure for deadly disease like cancer. 
Keywords: Epithelial tumor, mesenchymal tumor, cancer 
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2. INTRODUCTION: 
In this era of globalization with the aid of technological revolution the human society strive 
to make the overall quality of life better. But still there are some diseases which persist as a 
mystery yet to be unsolved. One such mystery is the mystery of tumors that may further lead 
to the deadly disease “CANCER” which is haunting every levels of the society around the 
world. Understanding and unraveling the complexity behind these tumors is a primary 
concern among the scientific community in present condition.  
Tumors are an abnormal mass of tissue which is solid or fluid-filled. They can either 
be benign (non cancerous) or malignant (cancerous). Benign tumors are restricted to grow at 
one place and they don’t invade the nearby tissue, whereas malignant tumor invade the 
adjacent tissues and show properties of metastasis i.e. the abnormal cell move from one area 
to another within the patient’s body. Therefore, malignant tumors shows high degree of 
aggressive growth compared to benign tumors (Weinberg, 2006). 
According to the International Classification of Diseases for Oncology, 3rd Edition 
(ICD-O-3), tumors are classified based upon the morphology and topography of the neoplasm 
into epithelial, connective tissue, nervous system and hematologic.   
Epithelial tumors begin in the skin or in the tissues that line or cover internal organs. 
They account for majority of tumors occurring all round the globe and mainly affect the 
organ systems like digestive, reproductive system etc. They are also known as carcinomas 
when they exhibit cancerous property. 
Mesenchymal tumors originate from the connective tissues, hence are also known as 
connective tissue tumors. Connective tissues include fat, tendons or other tissues that 
connect, surround or support the organs in the body. They can arise anywhere in the body but 
are most commonly found in arms, legs, retroperitonium (area behind the abdomen) and 
chest. When they show cancerous property, they are known as sarcomas. Carcinomas account 
for 80 to 90 percent of all cancer and sarcomas being relatively rare malignant tumors 
comprise less than 10% of all cancers (Jemal et al., 2003).   
Tumors of nervous system or neuroepithelial origin are derived from neurons, 
astrocytes, ependyma, oligodendrocytes or primitive embryonal cells. The most common type 
of tumor of nervous system is glioblastoma which is highly malignant astrocytic glial tumors 
with a fast pace of growth. 
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Hematologic tumor includes leukemias, lymphomas and other related disorders. 
Leukaemias are cancers that affect cells of blood and bone marrow. It starts in the bone 
marrow where blood cells develop and generally white blood cells undergo cancerous 
change. These cells multiply in a uncontrolled manner and affects the ability to synthesize 
normal cells. These abnormal cells are called blast cells or leukaemic blasts which come out 
of bone marrow and spread in the body through bloodstream. 
Lymphomas are a cancer that affects cells of immune system or lymphatic system 
known as lymphocytes. There are mainly two types of lymphomas Hodgkin and non-
hodgkin. Hodgkin lymphoma is marked by the occurrence of Reed-Sternberg cell and 
restricted to B-cells whereas non-hodgkin lymphoma can occur in either B-cell or T-cell and 
is further divided into indolent i.e. slow growing and aggressive i.e. fast growing. Both types 
of lymphomas can occur in adult as well as children. 
Out of all these tumors majority of the tumor originate from the tissues of epithelial origin. 
Then by the mechanism of epithelial to mesenchymal transition (EMT) they spread to other 
parts of the body leading to carcinoma invasion and metastasis. And when they reach 
different sites after metastasis these cells undergoes mesenchymal to epithelial transition 
(MET) mechanism for clonal outgrowth. By following these two mechanism i.e. EMT and 
MET the initiation as well as completion of the cancer metastasis is carried out (Chaffer 
and Weinberg, 2011). EMT which is a conserved cellular program was initially recognized 
during stages of embryonic development. It has recently been found to have a role in 
promoting carcinoma invasion and metastasis (Yang and Weinberg, 2008). This mechanism 
mainly allows the conversion of immotile epithelial cells to motile mesenchymal cells. By 
studying all these mechanisms and phenomenon we can think that how the behavior of one 
type of tissue influence the other tissue during cancer progression. And further if we think 
about the processes occurring at the cellular and molecular level the degree of complexity 
increases. The mechanism of EMT and MET are one such example among the various other 
processes occurring at the molecular level some of which are yet to be understood and 
discovered. 
Proper understanding and unveiling the mystery of the tumors particularly of these 
two origins i.e. epithelial and mesenchymal origin may help to uncover the phenomenon of 
cancer progression. The study for understanding the tumors at the molecular level can be 
done through microarray analysis which is array of huge amount of biological data on a 2D 
solid substrate by using high throughput screening method. The main aim of present study is 
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to understand the similarity and dissimilarity between tumors of epithelial and mesenchymal 
origin by microarray analysis. Microarray analysis of differentially expressed genes was done 
in Genespring software and gene ontology study was done in Genomatix software. These 
analysis lead to the selection of two genes for further study based upon their regulation and 
association with cancer. Expressions of these genes were confirmed in HeLa cell line which 
is a cervical cancer cell line taking beta actin (a housekeeping gene) as reference gene 
through qRT-PCR. This study can lead to possible discovery of genes that can be used 
biomarker for group of cancers based on their tissue of origin. It might give a clue on cancer 
metastasis as well. By this, efforts could be made to search for a successful biomarkers and 
subsequent treatment measure to cure this deadly disease with great efficacy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
Page | 4  
 
REVIEW OF LITERATURE 
3.1. Tumours 
When cells in a part of the body start to grow abnormally and uncontrollably, they are called 
tumour. They can be benign, premalignant or malignant. The cells of benign tumours are 
close to normal in appearance and do not have the potential of being dangerous. They grow 
slowly and do not invade nearby tissues or spread to other parts of the body. Pre-malignant 
tumors have the potential to become malignant, but the cells do not show the property of 
uncontrolled proliferation. On the other hand a malignant tumour is cancerous and can spread 
beyond the original tumor to other parts of the body by invading the normal tissue. One of the 
critical stages in the progression of malignant tumor is the loss of control of cell cycle 
regulation (Hartwell and Kastan, 1994). Cancers are named according to the place from 
where they first started irrespective of where they spread [According to the International 
Classification of Diseases for Oncology, 3rd Edition (ICD-O-3)] (fig.1). There are different 
types of cancer depending on their site of origin and each cancer behaves differently showing 
variation in their growth rates and response to various treatment measures. The main reason 
for such variations is the factors which influence the incidence of cancer. These factors 
include sex, age, diet, genetics and environmental factors (Alberts et al., 2002).  
 
Fig.1. Different kinds of tumors according to ICD-O-3 
 
The malignant tumors are characterized by some features typical to them (Slooten et al., 
1985; Nishida et al., 2006). It includes i) Moderate or great changes in the cells or tissues like 
necrosis, hemorrhage etc. ii) Formation of abnormal structures iii) Moderate or extensive 
abnormality in the structure of the nucleus and nucleoli iv) Hyperchromatic state of nucleus 
v) Formation of new blood and lymphatic vessels by the process called angiogenesis or 
lymphangiogenesis. 
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Malignant tumors, otherwise known as cancers mainly arise from 4 types of cells which 
includes epithelial cells, mesenchymal cells, hematopoietic cells (also constitutes cells of 
immune system) and cells of central and peripheral nervous system. Though there are 
exceptions like melanomas which don’t fit in any of the major classification (Weinberg, 
2006). 
3.2 Epithelial Tumors  
Most of the human tumors are of epithelial origin (Weinberg, 2006). Epithelial cells form the 
lining of the walls or cavities of the body. In case of skin it acts as the outer covering. 
Beneath it lays the basal membrane which separates epithelial cells from connective cells. 
Malignant epithelial tumors are also termed as carcinoma. Carcinoma is responsible for most 
of the cancer related death all around the world and includes mainly cancers of the mouth, 
esophagus, stomach, cervix, small and large intestine. It also comprises skin, lungs, liver gall 
bladder, urinary bladder, and ovarian cancers.  
Epithelial tissue arises from three of the primitive cell layer namely ectoderm, endoderm and 
mesoderm (Chuai et al., 2006). Epithelial cells have shown to have two major biological 
functions. They are:- 
i) To cover and close the cavity and protect the cell population present inside it. 
ii) Secretion of substances inside the cavities or ducts around which it form the lining. 
Based upon these two function carcinoma are divided into two major categories namely 
squamous cell carcinoma and adenocarcinoma (Weinberg, 2006). 
Squamous cell carcinoma arises from the cells which are mainly associated with formation of 
protective layer like lining of skin, esophagus etc. Squamous cell carcinoma of skin accounts 
for majority of skin cancer. 
Adenocarcinoma arises from the cells that secrete substances into the duct or cavity or 
glanular tissue. The main characteristics of adenocarcinoma are its secretory properties and 
association with gland. The name itself suggests the fact as “adeno” means pertaing to a 
gland and “carcinoma” means cancer (table1). 
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TABLE 1: Types of carcinoma and its site of occurrence 
  
3.2.1 Stomach Cancer 
Stomach cancer or Gastric Carcinoma stands second as the cause of death due to cancer 
worldwide (Nagini, 2012). The ratio of stomach carcinoma is higher than other common 
malignancies like breast cancer, prostate cancer etc. (Catalano et al., 2009). Though there is 
advancement in diagnosis process still majority of patients are not diagnosed at the earlier 
stage and later suffer from anemia and weight loss, during the advance stage as the body 
refuses meat based food (Nagini, 2012). It arises from an inflammation and has a long pre-
cancer period and then develops into cancer via numerous steps (Carl-McGrath et al., 2007). 
Stomach adenocarcinoma arises from the stomach mucosa containing neoplastic cells and 
develops into glanular like tubular structure which frequently ulcerate and is characterized by 
penetration and thickening of wall of the stomach (Nagini, 2012). It is responsible for 90-
95% of all gastric malignancies (Shang and Pena, 2005). 
Site of occurrence of squamous cell 
carcinoma 
Site of occurrence of adenocarcinoma 
Skin Lungs 
Tongue Stomach 
Cervix Colon 
Nasal Cavity Prostate 
Larynx Pancreas 
Oropharynx Rectum 
Lungs Ovary 
Esophagus Gall bladder 
Mouth Endometrium 
Parotid gland Esophagus 
Eyelid Breast 
 Cervix 
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3.2.2 Cervical Cancer 
Cervical cancer or cervical carcinoma is a sexually transmitted disease caused by infection of 
human papillomavirus (HPV) (Okechukwu, 2011). Worldwide study shows that HPV DNA 
is 99% associated with invading cervical cancer (Parkin, 2006; McLaughlin-Drubin, 2008). It 
is second most widespread cancer in women (Schiffman et al., 2007). The condition of 
developing country like India is worse. It is estimated that in India alone the cervical cancer 
patient were 100,000 in the year 2001(Shanta et al., 2001). Cervical cancer progression 
involves 4 steps which includes- i) Infection in the cervical transformation zone epithelium ii) 
Viral perseverance iii) Development of infected epithelium to precancer iv) Progression and 
invasion (Schiffman et al., 2007). 
3.3. Neuroepithelial Tumor 
In the year 1993 WHO gave a new and complete classification of neoplasm that affects the 
central nervous system. The classification was mainly based upon the foundation that tumors 
results from the anomalous growth of particular cell type. According to this classification 
neuroepithelial tumors includes: i) Astrocytic tumors (glial tumors) ii) Oligodendroglial 
tumors iii) Ependymal cell tumors iv) Mixed gliomas v) Neuroepithelial tumors of uncertain 
origin vi) Tumors of the choroid plexus vii) Neuronal and mixed neuronal-glial tumors viii) 
Pineal Parenchyma Tumors ix) Tumors with neuroblastic or glioblastic elements (embryonal 
tumors). 
3.3.1. Glioblastoma or Brain Cancer 
Glioblastoma is most fatal of all gliomas which are a set of tumors arising from glial cell in 
the central nervous system and it is a type of astrocytic tumor (Holland, 2000). Glioblastoma 
is most aggressive as the patient suffering from this disease dies within a year. Due to its 
complex nature this disease is hard to treat by therapeutic treatments (Holland, 2000). It 
develops resistance against cell death by switching from mitochondrial oxidative 
phosphorylation to cytoplasmic glycolysis (Michelakis et al., 2010). 
 
3.4. Mesenchymal Tumor 
Mesenchymal tumors are derived from numerous connective tissues present everywhere in 
the body and share common origin (Weinberg, 2006). Also known as sarcomas, they are 
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further classified on the basis of the site of the tumor: bone or soft tissue (Lahat et al., 2008). 
Of these, soft tissue sarcoma (STS) is the collective term used for malignancies arising in 
muscles, fat, vessels and fibrous tissues (WHO classification). Mesenchymal tumors can 
develop from tissues like muscle, nerves, fat, fibrous, blood vessels or deep skin tissues. They 
can be found in any part of the body mostly arms and legs, but can also be formed in the 
head, neck, trunk area and retroperitonium. These tumors are not common like carcinomas. 
Soft tissue sarcomas having complex karyotypes do not show characteristic mutation or 
fusion of genes and includes dedifferentiated and pleomorphic liposarcoma, leiomyosarcoma 
and myxofibrosarcoma (Barretina et al., 2010). 
3.4.1 Liposarcoma 
Liposarcoma arises mainly from soft tissue and the retroperitoneum and are classified into 5 
types based upon morphological characteristics: well-differentiated, myxoid, dedifferentiated, 
pleomorphic and round cell (Richard et al., 2010). Among all the soft tissue sarcoma 
liposarcoma is the most common and accounts for approximately 20% of all mesenchymal 
malignancies (Dei Tos, 2000). Pleomorphic liposarcoma is an uncommon type of 
liposarcoma which has recently been characterized properly (Hornick, 2004).  
3.4.2 Leiomyosarcoma 
Leiomyosarcoma is an uncommon malignant tumor of the smooth muscle cells. It is also 
found in the uterus and abdomen. There are different types of leiomyosarcoma like 
pleomorphic leiomyosarcoma, myxoid leiomyosarcoma, differentiated leiomyosarcoma etc. 
Pleomorphic leiomyosarcoma, due to its morphological feature and biological behavior was 
recently characterized as a variant and remains controversial (Oda et al., 2001). Myxoid 
leiomyosarcoma is a rare form of malignant tumor which is mainly found in the uterus but 
rarely found in other location (Rubin, 2000).  
 
3.4.3 Malignant Fibrous Histiocytoma (MFH) 
Malignant fibrous histiocytoma is said to be the common sarcoma of adults but is 
controversial both in terms of histogenesis and validity (Randall, 2004). The prognosis of 
MFH is poor (Konishi, 1984). These tumors show no signs of true histiocytic differentiation 
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and show no definable line of differentiation. World Health Organization classification now 
classifies MFH as distinct diagnostic category as undifferentiated pleomorphic sarcoma. 
 
3.5. Microarray Gene Expression Analysis 
Gene expression profiling is the measurement of expression of many genes at instant and 
using microarray this measurement can be carried out for previously identified genes. By this 
a global picture of cellular function can be created. Past few years has experienced a great 
change in microarrays for analyzing total genome of organisms and developed chips to 
measure the expression of 40,000 genes (Watson, 1998). This study encourages transparent 
design and makes the data available publically (Ioannidis, 2009). Microarrays data can be of 
different types like DNA microarray, RNA microarray, protein microarray, microbe 
microarray etc. Microarray gene expression data generated are deposited by various research 
groups in various databases. The various types of microarray database are: 
i) Gene Expression Omnibus (GEO) (from National Center for Biotechnology Information) 
ii) ArrayExpress (from European Bioinformatics Institute) 
iii) Stanford microarray database 
iv) caArray at NCI 
v) Genevestigator database 
By using microarrays one can measure the relative quantities of particular mRNAs in two or 
more samples of tissues for thousands of gene simultaneously (Kerr et al., 2000). Microarray 
analysis techniques are used in the interpretation of data generated from experiments carried 
out on different types of microarrays. This allows the researchers to explore the expression of 
a large number of genes and also entire genome in a single experiment. With the use of gene 
expression microarray analysis, the cellular differentiation and oncogenic pathways of 
malignant tumors could be found and by this biomarkers as well as therapeutic targets for 
these tumors could also be generated (Baird, 2005). 
Different softwares are used to analyze the microarray data. It includes: 
i) Genespring: It is widely used, commercially available software for microarray analysis. 
ii) R: It is free software for statistical computing and graphics. It works on a wide variety of 
platforms like UNIX platforms, Windows and MacOS. 
iii) Bioconductor: It is an open source software for analyzing genomic data particularly 
microarray data. 
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iv) TM4: It is a free set of software for microarray analysis and consists of four major 
applications: Microarray Data Manager (MADAM), Spotfinder, Microarray Data Analysis 
System (MIDAS), and Multiexperiment Viewer (MeV). 
v) Spotfire: It is commercially available software for microarray analysis. 
 
3.6. Gene Ontology Analysis 
Web based tools like Genomatix, DAVID Bioinformatics Resourses 6.7, National Cancer 
Institute Nature Pathway Interaction Database and Metacore were used for pathway analysis 
of the differentially expressed genes. Genomatix is web based software for microarray 
analysis. Pathway analysis and linkage of genes is carried out with this software (Abu-Asab 
et al., 2011). The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
provides comprehensive tool to understand meaning behind huge number of genes. This 
software provides functional annotation tools to the user and facilitates microarray analysis 
by analyzing differentially expressed genes (Liu et al., 2013). Matacore allows pathway 
analysis of OMICS data and helps to have a comprehensive study of genes and related 
pathway thereby exploring and identifying potential biomarker. It also allows to interpret 
global changes in the proteome (Chen et al., 2013). 
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Objective 1: 
Microarray expression analysis of tumors of epithelial and mesenchymal origin 
 
Objective 2: 
Identification of overlapping sets of differentially expressed genes expressed in tumors of 
epithelial origin  
 
Objective 3: 
Identification of overlapping sets of differentially expressed genes expressed in tumors of 
mesenchymal origin  
 
Objective 4: 
Molecular classification of tumors on the basis of common set of differentially expressed 
genes irrespective of their organ specific expression 
  
Objective 5: 
Identification of enriched molecular pathways 
 
Objective 6: 
Validation of expression of two genes that are comparatively highly up or down regulated 
 
 
 
 
 
 
 
 
  
 
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS: 
4.1. Gene Expression data: 
Gene expression is the process through which genetic information is used in the production of 
a functional gene product which mainly includes protein. But in case of non protein like 
rRNA or tRNA genes the product produced is functional RNA. The data generated by 
microarray hybridization experiments which represent the expression of a specific gene are 
called as gene expression data. 
Gene expression data are stored in databases and some of these databases include GEO (Gene 
Expression Omnibus), GXD (Gene Expression Database), Gene Expression Atlas etc. 
For our study the microarray data were retrieved from GEO database which is a public data 
depository of functional genomics data. The data was retrieved for normal (control) tissues 
and cancerous (test) tissues from the different GEO series records (GSE). Experimental data 
for control (Table 2) and test (Table 3) includes: 
 
TABLE 2: EXPERIMENTAL DATA FOR TUMORS OF EPITHELIAL ORIGIN:   
Sl. no                    CONTROL           TEST 
  1 Normal human stomach tissue  Primary gastric tumor 
  2 Normal brain tissue High grade glioblastoma 
  3 Normal cervix epithelium Cervical squamous cell carcinoma 
 
TABLE 3: EXPERIMENTAL DATA FOR TUMOR OF MESENCHYMAL ORIGIN: 
Sl. no                   CONTROL             TEST 
  1 Normal human fat tissue Soft tissue sarcoma (leiomyosarcoma) 
  2 Normal human fat tissue Soft tissue sarcoma (MFH:Pleiomorphic) 
  3 Normal human fat tissue Soft tissue sarcoma 
(liposarcoma:Pleiomorphic) 
 
The criterion for selecting these experimental data was their platform. The platform for all the 
data was same i.e. Affymetrix HG-U133A with GEO Platform accession number GPL96. 
Based on same platform six tumors were selected with three from epithelial origin and three 
from mesenchymal origin. The GEO accession number of the data is given in Table 4.  
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TABLE 4: EXPERIMENTAL DATA AND THEIR GEO ACCESSION NUMBER 
Sl.No Tumor Control accession number Test accession number 
1 Stomach GSE2361 GSE15456 
2 Brain GSE13471 GSE8692 
3 Cervical GSE9750 GSE9750 
4 Leiomyosarcoma GSE21122 GSE21122 
5 MFH:Pleiomorphic GSE21122 GSE21122 
6 Liposarcoma GSE21122 GSE21122 
 
4.2 Microarray analysis of gene expression data- 
4.2.1 Retrieval of gene expression data- 
From the above mentioned GSEs (a series record of GEO that links together a group of 
related samples and provides a focal point and description of the whole study) individual 
GEO samples (GSM) were selected. The samples were selected in triplicates; this was done 
to minimize the error rate. For each of the tumors three control experimental data and three 
test experimental data were selected. The selected GSM for each tumor is (Table 5): 
 
TABLE 5: SELECTED GSM FOR EACH TUMOR 
Sl. 
No. 
Tumor Control Test 
1 Stomach GSM44703 GSM387757 
  GSM44703 GSM387758 
  GSM44703 GSM387759 
2 Brain GSM339552 GSM215420 
  GSM339553 GSM215423 
  GSM339554 GSM215427 
3 Cervical GSM247188 GSM247650 
  GSM247189 GSM247651 
  GSM247190 GSM247652 
4 Leiomyosarcoma GSM528425 GSM528323 
  GSM528426 GSM528324 
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  GSM528427 GSM528328 
5 MFH:Pleiomorphic GSM528431 GSM528350 
  GSM528432 GSM528355 
  GSM528433 GSM528380 
6 Liposarcoma GSM528428 GSM528410 
  GSM528429 GSM528411 
  GSM528430 GSM528412 
 
The process of retrieving the data from GEO is: 
GEO profile database of NCBI is searched for studies relevant to our interests 
    
            Raw data in .CEL format was downloaded from the supplementary files 
provided 
   with each GSM at the end of the section 
  
                        After downloading the compressed files, they were unzipped 
 
                                  Files were renamed as control and test 
 
 These files were imported into GeneSpring software for microarray data 
analysis. 
4.2.2 Analysis of gene expression data 
Genespring GX software (GeneSpring GX 11; Agilent, Santa Clara, CA) was used for 
analyzing the gene expression data. This software provides powerful and accessible statistical 
tools for high-speed visualization and analysis of transcriptomics, genomics, proteomics and 
metabolomics data. It gives the user an interactive computing environment for understanding 
microarray data within a biological context. Genespring provides an integrative platform for 
multi-omic data analysis. Key feature of this software includes Gene-level expression 
analysis on all major microarray platforms, including Agilent, Affymetrix, and Illumina, 
microRNA analysis and identification of gene targets, correlative analysis on mRNA 
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expression and miRNA data, real-time PCR data analysis, NCBI Gene Expression Omnibus 
Importer tool for expression datasets.  
Steps followed for gene expression analysis in GeneSpring: 
1. The raw data files from GEO database were downloaded as a zip file. 
2. Then the files were unzipped, extracted and renamed according to the convenience. 
3. GeneSpring was run and a new project with new experiment was created. Experiment 
name was given then experiment and guided workflow type was selected.  
4. Data was uploaded in triplicates with the selected technology as Affymetrix Gene 
Chip-HG-U113A. Profile plot of Normalized intensity map values is obtained after 
Normalization of data. Data is normalized to 75th percentile of signal intensity to 
standardize each chip for cross-array comparison. Normalization is done mainly for 
eliminating redundancy and ensuring that the data make sense with minimum number 
of entities. 
5. Gene significance/ differentially expressed genes were found through ANOVA using the 
following parameters: Coefficient of variation <50%, P < 0.05, Benjamini-Hochberg 
false discovery rate as multiple testing correction. Genes were derived using ANOVA and 
fold change more than 2.0 filtered using the Volcano plot. 
6. With the genes with fold change >= 2.0 of tumors of epithelial origin venn diagram is 
used to obtain the common set of genes between the epithelial tumors. Similarly the 
common set of genes with fold change >= 2.0 is obtained for mesenchymal tumors. 
Using these two files sets we obtain the common set of gene between the two tumor 
type i.e epithelial and mesenchymal and also the exclusive set of genes which are 
specific for a particular tumor. 
7. The common set of genes obtained was exported along with their normalization 
values, gene symbol and Entrez gene IDs from the GeneSpring software as a tab 
delimited file for further analysis. 
8. Using the obtained common set of genes, clustering analysis was done in GeneSpring 
using Hierarchical clustering algorithm. The distance metrics used was pearson 
uncentered and the linkage rule used was average. 
4.2.3 Gene Ontology Analysis  
The common set of genes was analyzed using GO database (Gene Ontology database), 
various technologies like Genomatix and web based tools like Web based gene set analysis 
tool kit and their involvement in various pathways was studied. From the common set of 
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genes two genes were selected based upon their regulation and association with cancer for 
further validation by qRT-PCR. 
4.3 Experimental Validation 
4.3.1 Cell culture 
For our study HeLa cell line was taken, these are human cervical cancer cells. HeLa cell line 
are the first type of human cancer cell which are cultures continuously for experiments. It was 
first derived from cervical cancer cells in 1951 from a patient named Henrietta Lacks. The 
medium used for culturing the cell is MEM (Invitrogen; MEM with NEAA (non essential 
amino acids) and L-Glutamine) with 10% FBS (Fetal bovine serum from HIMEDIA) and 1% 
antibiotic solution (Penstrep solution from HIMEDIA). The culture flask containing the cell 
line is kept in the CO2 incubator with the level of CO2 maintained at 5%. With the utilization 
of medium the color of the medium changes from red to orange and then pale yellow because 
of change in pH of the medium.  
The steps for cell culture: 
 
1. The cells were harvested first. 
Cells were grown in suspension i.e. 1 x 107 cells. The number of cells was 
determined. The appropriate number of cells was pelleted by centrifuging for 5 min at 
300 x g in a centrifuge tube. Carefully removed all supernatant by aspiration 
completely from the cell culture medium. 
To trypsinize and collect cells: The number of cells was determined. The medium was 
aspirated, and the cells were washed with PBS. Then the PBS was aspirated, and 0.1–
0.25% trypsin in PBS was added. After the cells detach from the flask, medium 
(containing serum to inactivate the trypsin)was added , the cells were transferred  to 
an RNase-free glass or polypropylene centrifuge tube and centrifuged at 300 x g for 5 
min. The supernatant was aspirated completely, and proceeded to step 2.  
2. The cells was disrupted by adding Buffer RLT: 
For pelleted cells, loosen the cell pellet thoroughly by flicking the tube. 350 μl Buffer 
RLT was added. Vortexed or pipetted to mix, and ensured that no cell clumps were 
visible and proceeded to step 3. 
3. The lysate was homogenize for 30 s using a rotor–stator homogenizer and proceeded 
to step 4. 
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4.  1 volume of 70% ethanol was added to the homogenized lysate, and mixed well by 
pipetting.  Did not centrifuge.        
5. 700 μl of each sample was transferred from step 4, including any precipitate to each 
RNeasy spin column on the vacuum manifold. 
6. The vacuum was switched on and was applied until transfer was complete. Then 
switched off the vacuum and ventilated the vacuum manifold. 
7. 700 μl Buffer RW1was added to each RNeasy spin column. 
8. The vacuum was switched on and was applied until transfer was complete. Then 
switched off the vacuum and ventilated the vacuum manifold. 
9. 500 μl Buffer RPE was added to each RNeasy spin column. 
10. The vacuum was switched on and was applied until transfer was complete. Then 
switched off the vacuum and ventilated the vacuum manifold. 
11. 500 μl Buffer RPE was added to each RNeasy spin column. 
12. The vacuum was switched on and was applied until transfer was complete. Then 
switched off the vacuum and ventilated the vacuum manifold. 
13.  The RNeasy spin columns was removed from the vacuum manifold, and was placed 
each in a 2 ml collection tube. The lids were closed gently, and centrifuged at full 
speed for 1 min. 
14.  Each RNeasy spin column was placed in a new 1.5 ml collection tube. 30–50 μl 
RNase free water was added directly to each spin column membrane. The lids were 
closed gently, and centrifuged for 1 min at 8000 x g (10,000 rpm) to elute the RNA. 
15.  If the expected RNA yield is >30 μg, then step 15 was repeated using another 30–50 
μl RNase free water or using the eluate from step 14 (if high RNA concentration is 
required). The collection tubes were reused from step 14. 
 Note: If using the eluate from step 14, the RNA yield will be 15–30% less than that obtained 
using a second volume of RNase-free water, but the final RNA concentration will be higher. 
 
 
4.3.2 RNA Isolation  
RNA isolation is carried out using QIAGEN kit. The steps involved in the isolation of RNA:- 
1. A maximum of 1×107 cells were harvested as a cell pellet and the the appropriate 
volume of Buffer RLT (Lysis buffer) was added. 
2. 1 volume of 70% ethanol was added to the lysates and mixed well by pipetting. It 
should not be centrifuge.  
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3. 700 µl of the sample, including any precipitation was transfered to an RNeasy Mini 
spin column placed in a 2ml collection tube (supplied). It was centrifuged for 15s at 
≥8000×g (13,000 RPM). Flow –through was discarded. 
4. Then 700 µl Buffer RW1 (wash buffer) was added to the RNeasy spin column. It was 
centrifuged for 15s at ≥8000×g (13,000 rpm). Flow –through was discarded. 
5. 500 µl Buffer RPE (wash buffer) was then added to the RNeasy spin column. It was 
centrifuged for 15s at ≥8000×g (13,000 rpm). Flow –through was discarded. 
6. 500 µl Buffer RPE was again added to the RNeasy spin column. It was centrifuged 
for 15s at ≥8000×g (13,000 rpm). Flow –through was discarded. 
7. The RNeasy spin column was then placed in the new 1.5 ml collection tube and 30-50 
µl of RNase- free water was added directly to the spin column membrane. It was 
centrifuged for 15s at ≥8000×g (13,000 rpm) to elute the RNA. 
8. Using eppendorf nanodrop the purity and quantity of RNA yield is checked by taking 
only 1-2µl of the sample.  
 
 
 
Precaution: 
1. A clean and sterilized environment was maintained while working with the RNA as 
there is high chance of contamination by RNase which may degrade the RNA and 
lead to reduced RNA yield. 
2. When working with chemicals, always wear a suitable lab coat and disposable gloves. 
3. Contact of chemicals with acids should be prevented as the combination liberates very 
toxic gas. 
4. In case of contact with eyes, rinse immediately with plenty of water and seek medical 
advice. 
5. The chemicals are harmful if inhaled or if comes in contact with skin and if 
swallowed. 
 
 
4.3.3 cDNA synthesis 
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cDNA synthesis was carried out using SuperScript First-Strand Synthesis System for RT-
PCR by Invitrogen using oligo dT primers. 
The steps in cDNA synthesis: 
1. Each component of the kit was mixed and briefly centrifuge before use. 
2. For each reaction, the following components were combined in a sterile 0.2 or 0.5ml 
tube. 
 
Components 
 Amount 
RNA (2µg) 
 n µl 
10 mM dNTP mix 
 1 µl 
Primer (0.5µg/µl oligo (dT)12-18) 1µl 
DEPC treated water To 10µl 
 
3. The RNA/primer mixture was incubated at 65·c for 5 minutes and then placed on ice 
for at least 1 minute.  
4. In a separation tube, the following 2X reaction mix was prepared, by adding each 
component in the indicated order. 
 
Components 
 1RXn 10 RXnS 
10X RT buffer 
 2 µl 20 µl 
25mM Mgcl2 
 4 µl 40 µl 
0.1M DTT 
 2 µl 20 µl 
RNase out TM (400/ 
µl) 
 
1 µl 10µl 
 
5. 9µl of the 2X reaction mixture was added to each RNA/primer mixture from step 3 
and mixed gently and collect by briefly centrifugation. 
6. It was incubated at 42·c for 2 minutes. 
7. 1µl of super scriptTM II RT was then added to each tube 
8. Incubated at 42·c for 50 minutes 
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9. Then, the reaction is terminated at 70·c for 15 minutes and chilled on ice 
10. The reaction was collected by brief centrifugation and 1µl of RNase H was added to 
each tube and incubated for 20 minutes at 37·c. 
11. Then, the reaction is stored at -20·c or used for PCR immediately. 
4.3.4 qRT-PCR 
Real time PCR is a method that allows exponential amplification of DNA sequences and 
simultaneously quantifies it. This system is based on the detection and quantitation of a 
fluorescent probes. Probes which are used in qRT-PCR are taqman probes, molecular beacon 
, SYBR® Green, displacing probes, light up probes etc. For present study we used SYBR® 
Green probe which is a frequently used fluorescent DNA binding probe and relies on the 
sequence specific detection dye. The genes which are taken for the experiment are of two 
types test genes and reference genes. Reference genes are used to compare the expression of 
test genes i.e. how much fold they have increased or decreased with respect to normal 
expression. Reference genes should have following feature: the standard gene should have 
the same copy number in all cells, it should be expressed in all cells, a medium copy number 
is advantageous since the correction should be more accurate. For this experiment the test 
genes were ABCA8 and SMC4 and reference gene used is beta-actin. Beta actin is a house 
keeping gene also called as constitutive genes which are required for the maintenance of 
fundamental cellular function, and are expressed in all cells of an organism under normal and 
patho-physiological conditions. Cycle temperature and time is mentioned in Table.6. and 
fig.2. 
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Table 6: Cycle Temperature and time for real time PCR 
 
 
 
      Fig.2. Cycle temperature and time of qRT-PCR 
 
The  The total reaction volume could either be 5µl or 10µl. We prepared total reaction 
volume of 10µl. 
Calculation: 
We took 3 genes, therefore, 
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                   3 genes x 3 replicates = 9 x 10 = 90µl 
                                                                     =100µl (in case of pipetting error do addional  
                                                                                  10 µl is taken) 
i) SYBR ® Green master mix:- 
The stock solution is 2X concentration and working solution of 1 X concentration is 
prepared. 
                            2X x  (? µl) = 1X x 100µl 
Ö      (? µl) = 1X x 100µl / 2X 
             = 50µl 
SYBR ® Green master mix= 50µl 
ii) cDNA: 
                  cDNA =  cDNA stock : distilled water 
                                                     1 : 20 
cDNA=3µl 
Distilled water = 57µl 
Total= 3+57 µl=60µl 
 
For each reaction we require 4µl of cDNA 
Therefore, for 10 reaction= 4x10= 40µl 
From the above made 60 µl we took 40µl 
iii) Primer:- The stock solution contains 10µM, we require 500nM for each reaction 
                      10 µM x  (? µl) = 500x1000µMx100 
Ö      (? µl) = 500x1000µMx100 /  10 µM 
Ö                = 5µl 
For forward and reverse primer 5x2=10µl 
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SYBR ® Green master mix + cDNA + Primer= (50 +40+10) µl= 100 µl 
                                                100µl 
 
 
Gene 1         Gene 2            Gene 3  
                             For each gene 3 replicates is taken 
The primer sequences were obtained from Primer Bank Harward and ordered from Sigma 
Genosys and sequence for each gene is: 
 
 
 
Reference gene:                                                                             Amlicon Size 
Beta actin:                                                                                          250 
Forward primer- CATGTACGTTGCTATCCAGGC 
Reverse primer- CTCCTTAATGTCACGCACGAT 
 
Test Gene: 
a) ABCA8:                                                                                          176 
Forward primer- TTCATGTTGGCATTTGACACTTG 
Reverse primer- GGATCGGCATCCATTTCATCT 
b) SMC4:                                                                                              87 
Forward primer- CGCCTCCAGCAATGACCAAT 
Reverse primer- CCCCAGCATAGGATTTGAAGTT 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSIONS 
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RESULTS AND DISCUSSIONS: 
5.1 Microarray analysis  
From microarray analysis using Genespring, we got differentially set of genes for each of the 
cancer types considered in our study with fold change (FC) >=2.0. Thereafter, we obtained 
344 differentially expressed genes (up/down) which are common among the tumors of 
epithelial origin. 
 
Fig.3. Venn diagram showing common set of differentially expressed genes among 
epithelial tumors 
From this analysis, we not only got the common set of genes between tumors of 
epithelial origin, but also got the exclusive genes that are expressed in brain, cervical and 
stomach cancer.  
Similarly, we got 672 genes which are differentially expressed in all tumors of mesenchymal 
origin. 
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Fig.4. Venn diagram showing common set of differentially expressed genes among 
mesenchymal tumors 
From the common set of differentially expressed genes between tumors of epithetlial and 
mesenchymal origin, we got the genes which are common to both epithelial and 
mesenchymal tumors. 
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Fig.5. Common set of genes between epithelial and mesenchymal tumors 
               Total of 107 genes were obtained which upon further screening, i.e. removal of 
redundant data or similar probe set id, yielded 89 genes which are common to both tumors of 
epithelial origin and mesenchymal origin. 
               Considering the 89 common genes and their normalization intensity values, we did 
the hierarchical clustering of these six tumors and obtained the following dendrogram. The 
dendrogram shows that cervical and stomach cancer clustered together, but brain cancer 
clustered separately it may be due to the neuroepithelial origin of brain cancer. Even though 
brain cancer is grouped differently than other cancers, it is still closer to rest two cancers of 
epithelial origin. Tumors of mesenchymal origin clustered together. 
The classification mainly formed two clusters one of epithelial tumors and other of mesenchymal 
tumors. 
 
 
  
 
Fig.6. Clustering of common differentially expressed genes  
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5.2. Gene Ontology Analysis 
The 89 genes were analyzed using genomatrix to see if they belong to same or common 
pathway. 
From the analysis we got two enriched pathway: PLK1 pathway and FOXM1 transcription 
network 
a) Polo Like Kinase 1 (PLK1)  pathway: 
¾ PLK1 was found to have a critical role in many cancers (both epithelial and 
mesenchymal origin)   because of its role in mitotic progression 
15 genes from the common set of genes were present in PLK1 pathway. 
Analysis of 15 genes that was present in enriched PLK1 pathway showed that the regulation 
of each of the 15 genes were similar in both epithelial and mesenchymal tumor. 
 
 
 
 
Fig.7. PLK1 pathway having 15 genes from common set of 89 genes 
          By default a gene product is drawn as rounded rectangle 
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           kinase 
 
           phosphatase 
 
           receptor 
 
           transporter 
 
           co-factor 
 
            RNA 
 
2 genes are associated by co-citation. 
 
2 genes are associated by expert-curation. 
 
Gene A activates Gene B. 
 
Gene A inhibits Gene B. 
 
Gene A modulates Gene B. 
 
Gene A alters the state of Gene B. 
 
If gene A has a known TF binding site matrix and gene B has a corresponding binding site in 
one of its promoters the arrow is filled black. For interactions that involve a complex, this 
arrow type is never used. To look for promoter bindings in this case, double-click on the edge 
and select the interaction of interest. 
 
There is no promoter binding noted 
 
b) FOXM1 transcription network 
¾       FOXM1 , a transcription factor was also found to be regulated by pathways 
involved in cancers  
7 genes from the common set of genes were present in the FOXM1 transcription 
network(fig.6). 
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Fig.8. FOXM1 transcription factor network having 7 genes from common set of 89 
genes 
From the pool of 89 the common genes that are differentially expressed in both tumors of 
epithelial & mesenchymal origin, we selected only two genes (ABCA8 and SMC4) for 
further study and experimental validation in cancer cell lines. 
The official full name of ABCA8 is ATP-binding cassette, sub-family A (ABC1), 
member 8. It is a membrane-associated gene which encodes for a member of the superfamily 
of ATP-binding cassette (ABC) transporters. ABCA8 is a member of ABC1 subfamily and 
found exclusively in multicellular eukaryotes. The function of this gene is yet to be 
discovered. Direct association of ABCA8 with cancer is not seen but it is seen to be 
downregulated in drug resistant ovarian cancer cell line (Januchowski et al, 2013), in tongue 
squamous cell carcinoma (Ye et al., 2008). 
The official full name of SMC4 is structural maintenance of chromosomes 4. It is a 
member of structural maintenance of chromosomes, or SMC, family. They are responsible 
for mitotic chromosome condensation in frogs and for DNA repair in mammals. Studies 
suggest that SMC4 is associated with tumorigenesis. Overexpression of the SMC 4 protein is 
associated with tumor de-differentiation, advanced stage and vascular invasion of  primary 
liver cancer (Zhou et al., 2012). 
Both the genes have function in ATP binding. They are associated with respiratory diseases 
like pneumonia. 
From genespring analysis we got that ABCA8 was upregulated and SMC4 was 
downregulated. 
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Interaction network of all the 89 common genes with two of our gene of 
interest is described below (fig.7): 
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Fig.9. Interaction map of 89 genes with our 2 genes of interest 
5.3 Experimental validation 
5.3.1. RNA Isolation 
The yield after RNA isolation was: 
RNA conc. – 498.3µl 
2.00-260/280 
2.00-260/230 
260/280 
The ratio of absorbance at 260 nm and 280 nm is used to measure the purity of DNA and 
RNA. A ratio of ~1.8 is usually accepted as “pure” for DNA; a ratio of ~2.0 is usually 
accepted as “pure” for RNA. If the ratio is significantly lower in each case, it may show the 
presence of protein, phenol or other contaminants that absorb strongly at or near 280 nm. 
260/230     
This ratio is used as a secondary measure of nucleic acid purity. The 260/230 values for 
“pure” nucleic acid are frequently higher than the respective 260/280 values. 260/230 values 
are normally in the range of 2.0-2.2. If the ratio is significantly lower than expected, it may 
indicate the presence of contaminants which absorb at 230 nm. EDTA, carbohydrates and 
phenol all have absorbance near 230 nm. 
5.3.2. qRT PCR 
Melting curve analysis is an assessment of the dissociation of ds DNA during the process of 
heating. As the temp increases the double strand of the DNA starts to separate leading to a 
rise in the absorbance. The temp at which 50% of DNA is denatured is known as the melting 
point. The graphical curve obtained from the real time PCR because of the 50% denaturation 
of DNA  is known as melting temperature curve. The melting temperature curve of ABCA8 
and SMC4 is shown below: 
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  Fig.10. Melting temperature curve of ABCA8 and beta-actin 
 
Fig.11. Melting temperature curve of SMC4 and beta-actin 
 
 
 
Relative quantification is the measure of increase or decrease in fold change with respect to 
the reference or control gene.  
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Fig.12. Relative expression of SMC4 and ABCA8 with respect to control 
qRT- PCR confirms the presence of SMC4 and ABCA8. Both the genes were found to be 
upregulated in qRT-PCR results. SMC4 was found to be highly upregulated with respect to 
control gene beta-actin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 10
ABCA8
SMC4
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CONCLUSION: 
Our microarray analyses of samples of cancers of different tissue origin lead to sets of 
differentially expressed genes. We found 344 genes are differentially expressed in tumors of 
epithelial origin, whereas 672 genes in tumors of mesenchymal origin. Our subsequent 
analysis lead to 89 genes that was common to both the tumor types. Based on the 
normalization intensity values of these 89 genes, we were able to cluster the two malignant 
tumors. Cluster analysis of cancers of epithelial and mesenchymal origin using expression 
values of these common genes shows their classification according to their tissue of origin. 
This is in accordance with the International classification of Diseases of oncology which 
classifies cancers according to morphology and topography. Brain cancer, which originates 
from epithelial cells forms a different group in our clustering result, which might be because 
of its neuro-epithelial nature. These two tumors share similarity as well as dissimilarity 
among them which is evident from our study through the clustering analysis. 
Gene ontology study of 89 genes through genomatix software gave us two enriched 
molecular pathway, PLK1 signaling pathway and FOXM1 transcription signaling pathway 
which contain 15 and 7 genes respectively. These two pathways are reported to play critical 
role in many malignant tumors. Furthermore, we selected two genes (ABCA8 and SMC4) for 
experimental validation based on their fold change & hypothesis that these two genes might 
have critical role in cancer. ABCA8 is ATP-binding cassette sub-family A (ABC1), member 
8. The function of this gene is yet to be discovered and SMC4 is structural maintenance of 
chromosomes 4. They are responsible for mitotic chromosome condensation in frogs and for 
DNA repair in mammals. Validation of expression of the two genes- ABCA8 and SMC4 by 
qRT PCR confirmed their expression in the HeLa cell line (cervical cancer cell lines). Further 
functional annotation of these genes as well validation of these genes in other cancer cell 
lines might provide deeper insight into their role in cancer biology. 
These 89 differentially expressed common genes in all the six malignant tumors and 
normal cells or subset of it can be used as possible biomarkers for cancers. By using 
standardized gene expression profile, one can predict cancer types and/or their tissue of origin 
even though it has been metastasized to other location. These gene profiles can be used as 
molecular signature to predict a medical condition of a cancer without prior knowledge of 
their tissue of origin or disease-specific symptoms. 
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